Stephen E Spurgeon

Trials

Studies that name Stephen E Spurgeon as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:45 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT06895473 · Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome

  OHSU Knight Cancer Institute · recruiting · Hematopoietic and Lymphatic System Neoplasm · principal investigator
• Ph1/Ph2
  NCT06357676 · Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

  OHSU Knight Cancer Institute · recruiting · Mantle Cell Lymphoma · principal investigator
• Ph1/Ph2
  NCT06249191 · Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

  OHSU Knight Cancer Institute · recruiting · Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma · principal investigator
• Ph1
  NCT05943496 · Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

  OHSU Knight Cancer Institute · recruiting · Chronic Lymphocytic Leukemia · principal investigator
• Ph2
  NCT02736617 · Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma

  OHSU Knight Cancer Institute · completed · Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 06:45 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.